-
公开(公告)号：EP2250165B1
公开(公告)日：2018-07-25
申请号：EP08864598.1
申请日：2008-12-17
申请人： Merck Serono S.A.
发明人： QUATTROPANI, Anna , CLEVA, Christophe , SEBILLE, Eric , SCHWARZ, Matthias , MARIN, Delphine , BOMBRUN, Agnès , BLACKABY, Wesley , ROUSE, Craig , KNIGHT, Chris , BAKER-GLENN, Charles
IPC分类号： C07D413/04 , C07D413/14 , A61K31/4245 , A61P37/00
CPC分类号： C07D413/04 , C07D413/14
摘要： The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, X have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
-
2.发明授权
公开(公告)号：EP2440554B1
公开(公告)日：2016-10-05
申请号：EP10724789.2
申请日：2010-06-07
申请人： Merck Serono S.A.
IPC分类号： C07D413/04 , C07D413/14 , C07D471/04 , A61K31/4245 , A61P37/06
CPC分类号： C07D231/10 , C07D271/06 , C07D413/04 , C07D413/14 , C07D471/04
-
公开(公告)号：EP2471817B1
公开(公告)日：2016-03-16
申请号：EP12161272.5
申请日：2008-12-08
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/92
-
4.发明公开Humanized antibody molecules specific for IL-31 有权F-IL-31 spezifische humanisierteAntikörpermoleküle
公开(公告)号：EP2796466A2
公开(公告)日：2014-10-29
申请号：EP14175301.2
申请日：2008-12-08
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： There is provided an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to human IL-31 comprising a humanized heavy chain variable domain and a humanized light chain variable domain, wherein the humanized heavy chain variable domain comprises a CDR1, CDR2 and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 1, 2 and 3, respectively, and framework regions FR1, FR2, FR3, and FR4 having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:12 (FR1), SEQ ID NO:13 (FR2), SEQ ID NO:14 (FR3) and SEQ ID NO:15 (FR4) respectively; and wherein the humanized light chain variable domain comprises a CDR1, CDR2 and CDR3 consisting of the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and framework regions FR1, FR2, FR3, and FR4 having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:17 (FR5), SEQ ID NO:18 (FR6), SEQ ID NO:19 (FR7) and SEQ ID NO:20 (FR8) respectively.
摘要翻译： 提供了特异性结合包含人源化重链可变结构域和人源化轻链可变结构域的人IL-31的分离的单克隆抗体或其抗原结合片段，其中人源化重链可变结构域包含CDR1，CDR2和CDR3 分别由SEQ ID NO：1,2和3的氨基酸序列组成，并且具有与SEQ ID NO：1,2和3的氨基酸序列至少90％相同的氨基酸序列的构架区FR1，FR2，FR3和FR4 分别为NO：12（FR1），SEQ ID NO：13（FR2），SEQ ID NO：14（FR3）和SEQ ID NO：15（FR4） 并且其中所述人源化轻链可变结构域分别包含由SEQ ID NO：5,6和7的氨基酸序列组成的CDR1，CDR2和CDR3，以及具有氨基酸序列的构架区FR1，FR2，FR3和FR4 分别与SEQ ID NO：17（FR5），SEQ ID NO：18（FR6），SEQ ID NO：19（FR7）和SEQ ID NO：20（FR8）的氨基酸序列至少90％相同。
-
公开(公告)号：EP2262702B1
公开(公告)日：2014-03-05
申请号：EP09729585.1
申请日：2009-03-31
申请人： Merck Serono S.A.
IPC分类号： B65D83/04
CPC分类号： B65D83/0463 , A61J1/035 , B65D2215/02 , B65D2215/04
-
公开(公告)号：EP2473850A1
公开(公告)日：2012-07-11
申请号：EP10747059.3
申请日：2010-08-30
申请人： Merck Serono S.A.
CPC分类号： G01N33/74 , A61K38/27 , C12Q1/6883 , C12Q2600/118 , G01N2333/4745 , G01N2333/65 , G01N2800/52 , G01N2800/60
摘要： The present invention relates to methods of predicting the level of response to treatment with growth hormone in an individual having Growth Hormone Deficiency (GHD) or Turner Syndrome (TS).
-
公开(公告)号：EP2367951A1
公开(公告)日：2011-09-28
申请号：EP09756527.9
申请日：2009-11-25
申请人： Merck Serono S.A.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
-
公开(公告)号：EP4070800A1
公开(公告)日：2022-10-12
申请号：EP22166610.0
申请日：2005-12-20
申请人： Merck Serono S.A.
IPC分类号： A61K31/7076 , A61K38/21 , A61P25/00 , A61P25/28
摘要： The present invention is related to a Cladribine dosage regimen for use in the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the Cladribine is orally administered and wherein re-treatments are possible.
-
公开(公告)号：EP2118076B1
公开(公告)日：2019-09-04
申请号：EP08709145.0
申请日：2008-02-21
申请人： Merck Serono S.A.
发明人： GAILLARD, Pascale , POMEL, Vincent , JEANCLAUDE-ETTER, Isabelle , DORBAIS, Jérôme , KLICIC, Jasna , MONTAGNE, Cyril
IPC分类号： C07D241/44 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D407/12 , C07D407/14 , C07D409/14 , C07D451/02 , A61K31/498 , A61P35/00
-
10.发明公开
公开(公告)号：EP3400217A1
公开(公告)日：2018-11-14
申请号：EP17700392.8
申请日：2017-01-04
申请人： Merck Serono S.A.
发明人： NAXOS PAGE, Patrick , SCHWARZ, Matthias , JORAND-LEBRUN, Catherine , QUATTROPANI, Anna , POMEL, Vincent
IPC分类号： C07D277/06 , A61K31/426 , A61K45/06 , A61P15/00 , A61P15/06
CPC分类号： C07D277/06 , A61K31/426 , A61K31/4422 , A61K45/06 , A61K2300/00 , A61K38/11
摘要： The invention provides the L-valinate ester of a hydroxypropylthiazolidine carboxamide derivative of formula (I), (2S)-3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1- phenylpropyl]-1,3-thiazolidine-2- carboxamide, as well as salts and crystal polymorphs thereof. The compound inhibits the prostaglandin F receptor (PGF2alpha) and is useful in the treatment of disorders such as preterm labor at the early gestational stage or dysmennorrhea.
-
-
-
-
-
-
-
-
-
搜索结果
83 条记录 (耗时 0.034 秒)
